Oral semaglutide demonstrated cardiovascular safety in people ...
SAN FRANCISCO, June 12, 2019 /PRNewswire-AsiaNet / -- Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. T...
Authors: LATEST ASIANET NEWS RELEASES